Search

Your search keyword '"Corvò, R"' showing total 532 results
Start Over Author "Corvò, R"
532 results on '"Corvò, R"'

153. Locally advanced non-metastatic breast cancer: Analysis of prognostic factors in 125 patients homogeneously treated with a combined modality approach

Author

Gardin, G., primary, Rosso, R., additional, Campora, E., additional, Repetto, L., additional, Naso, C., additional, Canavese, G., additional, Catturich, A., additional, Corvò, R., additional, Guenzi, M., additional, Pronzato, P., additional, Baldini, E., additional, and Conte, P.F., additional

Published
1995
Full Text
View/download PDF

156. Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck: results from a phase III randomized trial.

Author

Corvò, Renzo, Benasso, Marco, Sanguineti, Giuseppe, Lionetto, Rita, Bacigalupo, Almalina, Margarino, Giovanni, Pallestrini, Eugenio, Merlano, Marco, Vitale, Vito, Rosso, Riccardo, Corvò, R, Benasso, M, Sanguineti, G, Lionetto, R, Bacigalupo, A, Margarino, G, Pallestrini, E, Merlano, M, Vitale, V, and Rosso, R

Published
2001
Full Text
View/download PDF

159. Tomografia computerizzata e risonanza magnetica nella patologia del distretto testa collo: Parte terza: Indicazioni alla radioterapia dei carcinomi e monitoraggio dei pazienti nella valutazione dell'efficacia del trattamento

Author

Roncallo, F., Turtulici, I., Bartolini, A., Corvò, R., Sanguineti, G., Vitale, V., Margarino, G., Scala, M., Mereu, P., and Badellino, F.

Abstract

Scopo del lavoro è quello di delineare le indicazioni generali alla radioterapia, definitiva o in associazione alla chirurgia, nei pazienti affetti da carcinoma del distretto testa-collo, anche sulla base delle informazioni TC ed RM, e di descrivere le alterazioni morfologiche radiologiche che emergono, differenziando quelle suggestive di persistenza o recidiva neoplastica, da quelle indotte dalla radioterapia. Sono stati selezionati 95 pazienti che hanno praticato radioterapia come unico trattamento o in associazione alla chirurgia. Il primo controllo radiologico è stato effettuato di norma in un periodo di tempo compreso tra i 3 e i 4, 5 mesi dal termine della radioterapia. I pazienti sono stati seguiti nel tempo con esami seriati rispettivamente a 6, 9 e 12 mesi a distanza dal termine della radioterapia, a seconda dei rilievi emersi al primo controllo a ciclo terapeutico ultimato.Per quanto concerne la valutazione della risposta del tumore primitivo alla radioterapia sono stati distinti tre gruppi di pazienti. Il primo gruppo comprende soggetti nei quali il tumore primitivo, valutato alla TC e/o RM prima del trattamento radioterapico, ha dimostrato una regressione volumetrica superiore al 75% nei controlli tra i 3 ed i 12 mesi dalla fine del ciclo terapeutico (31 pazienti). Il secondo gruppo comprende soggetti nei quali il volume tissutale residuo dopo radioterapia, nei controlli a tre mesi, ha dimostrato una regressione inferiore al 50%, una persistenza o addirittura una progressione (44 pazienti).Un terzo gruppo è costituito da soggetti nei quali la regressione volumetrica del tessuto neoplastico nel controllo a tre mesi dal termine del ciclo terapeutico radioterapico è compresa tra il 50 ed il 75%. Quest'ultimo gruppo è quello che pone i maggiori problemi diagnostici e che viene seguito con controlli seriati ogni tre mesi, anche in presenza di negatività degli esami clinici ed endoscopici (20 pazienti).Le alterazioni tissutali post-radioterapiche sono state distinte in transitorie e permanenti. Quelle transitorie hanno raggiunto il massimo della loro espressività al termine del ciclo di trattamento, con visualizzazione di una massa conglomerata più estesa del tumore primitivo.Quelle permanenti si sono verificate a carico dei tessuti superficiali (ispessimenti della cute e del platisma, addensamenti nel tessuto adiposo sottocutaneo), nei piani fasciali profondi periviscerali (fibrosi del connettivo lasso adiposo parafaringeo, cervicale anteriore e posteriore, pericarotideo), nelle logge salivari (scialoadenite reattiva e degenerazione grassa), a livello degli spazi mucosi profondi (ispessimento simmetrico e infiltrazione delle pliche ariepiglottiche e delle corde vocali false, obliterazione dei piani adiposi pre- e paraglottici).La difficoltà di interpretazione delle immagini, con particolare riguardo ai possibili falsi positivi e falsi negativi, rappresenta soltanto una delle diverse facce della complessa problematica in corso di carcinoma del distretto testa-collo. Infatti i quesiti da risolvere coinvolgono anche il clinico, il chirurgo, il radioterapista oltre che il radiologo, il cui sforzo comune deve essere quello di garantire al paziente la migliore terapia possibile a fronte di una qualità di vita accettabile.

Published
1996
Full Text
View/download PDF

160. [Total body irradiation, vincristine in continuous infusion and high-dose melphalan with transplant of autologous bone marrow in the treatment of neuroblastoma]

Author

Dini G, Garaventa A, Lanino E, Gp, Perin, Scarpati D, Viscoli C, Franchini E, Corvò R, Sandro Dallorso, and Cinollo G

Subjects
Male, Neutropenia, Infant, Infections, Combined Modality Therapy, Neuroblastoma, Vincristine, Child, Preschool, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Child, Infusions, Intravenous, Melphalan, Whole-Body Irradiation, Bone Marrow Transplantation
Abstract

High dose chemo-radiotherapy followed by autologous bone marrow transplantation (ABMT) is known to be an effective treatment in stage IV neuroblastoma (NB). Since October '84, 19 children with NB (12 relapsed or resistant: Group A; 7 in first CR: Group B) received ablative therapy (AT) consisting of VCR (4 mg/mg), L-PAM (140 mg/mg) and fractionated TBI (1000 Rads). Induction strategy at diagnosis or at relapse included high dose Peptichemio, 2-3 cycles of Vincristine-Cyclophosphamide--high dose Platinum and surgery. Bone marrow was harvested after 2 evaluation proved negative by cytomorphology, histology and immunofluorescence. Mononuclear cells (median 6.7 x 10(7)/kg) were cryopreserved and reinfused without purging. At the time of AT in Group A8 children were in CR, 4 had minimal diseases; in Group B 6 were in CR and one in PR. One toxicity-related death occurred on day 7 in a child in first CR; median duration of granulocytopenia 0.5 x 10(9)/l and thrombocytopenia less than 50 x 10(9)/l were 20 days (R: 9-40) and 27 days (R: 11-51) respectively. Persistent immune thrombocytopenia occurred in 4 children. Fever higher tha 38 degrees C developed in all patients: sepsis was documented in 6 patients. Extramedullary toxicity was moderate: GI tract was the most affected. Two out of 5 children who received AT having residual disease achieved CR; relapse or progression of disease occurred in all these patients. Four out of 8 children in second or subsequent CR and 4 out of 5 in first CR are alive and well at 3-12 months (median 7).(ABSTRACT TRUNCATED AT 250 WORDS)

Published
1987

162. Efficacy and feasibility of induction chemotherapy and radiotherapy plus cetuximab in head and neck cancer

Author

Bacigalupo, A., Balcet, V., Bustreo, S., Corvò, R., Iotti, C., Lastrucci, L., Munoz, F., Musu, A., Piva, C., Riccardo Ragona, Rampino, M., Reali, A., Ricardi, U., Russi, E., and Schena, M.

Subjects
Bridged-Ring Compounds, Male, Maximum Tolerated Dose, Remission Induction, Antibodies, Monoclonal, Cetuximab, Chemoradiotherapy, Induction Chemotherapy, Middle Aged, Antibodies, Monoclonal, Humanized, Survival Rate, Treatment Outcome, Head and Neck Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Feasibility Studies, Humans, Female, Taxoids, Fluorouracil, Cisplatin, Aged, Follow-Up Studies, Neoplasm Staging
Abstract

To determine the potential activity and tolerability of sequential treatment in head and neck cancer, we conducted a phase II trial based on induction chemotherapy of two cycles of taxotere, cisplatin and 5-fluorouracil followed by radiotherapy plus weekly cetuximab.Thirty-six patients with stage III or IV squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx were treated and evaluated for response and acute toxicity.Eighty-one percent of patients had stage IV disease and 42% had hypopharyngeal and oral cavity primaries. The overall response rate was 81.8%, with 60.6% complete response and 33.3% partial response. Severe toxicities were febrile neutropenia (6%) during induction chemotherapy and dermatitis (48%), mucositis (33%) and dysphagia (12%) during the concurrent phase.Our protocol proved to be feasible, effective and well tolerated. This sequential strategy should be further investigated.

163. A Two-step Selection of Breast Cancer Patients Candidates for Exclusive IORT with Electrons: A Mono-institutional Experience

Author

Guenzi M, Fozza A, Timon G, Belgioia L, Vidano G, Cavagnetto F, Agostinelli S, Marco Gusinu, Carli F, Cafiero F, Friedman D, Canavese G, and Corvò R

Subjects
Decision process, Intraoperative Care, Breast cancer, Intraoperative radiation therapy, Humans, Breast Neoplasms, Dose-Response Relationship, Radiation, Electrons, Female, Pilot Projects, Prospective Studies, Combined Modality Therapy
Abstract

To assess the impact of a two-step multiparameter selection on the actual enrollment of women with breast cancer into a prospective intraoperative radiotherapy (IORT) trial.From September 2009, a prospective clinical trial was started in order to deliver adjuvant exclusive single -fraction IORT to patients with early breast cancer. To select patients meeting suitable eligibility criteria for the clinical trial, a two-step decision process was developed: at pre-surgical examination (first step) and during surgery (second step).A series of 464 patients with breast cancer was analysed: at the first step, out of 464 patients, 333 (71%) were considered eligible for the IORT protocol; at the second step, out of 333 patients, 199 (60%) met the eligibility criteria and received the IORT fraction according to the criteria of the controlled trial.In our experience, the ultimate rate of patients who enrolled in the IORT clinical trial after the two-step decision process was 43%.

166. Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: The Pros-IT CNR study

Author

Angelo, Porreca, Marianna, Noale, Walter, Artibani, Pier Francesco Bassi, Filippo, Bertoni, Sergio, Bracarda, Giario Natale Conti, Renzo, Corvò, Mauro, Gacci, Pierpaolo, Graziotti, Magrini, STEFANO MARIA, Vincenzo, Mirone, Rodolfo, Montironi, Giovanni, Muto, Stefano, Pecoraro, Umberto, Ricardi, Elvio, Russi, Andrea, Tubaro, Vittorina, Zagonel, Gaetano, Crepaldi, Stefania, Maggi, Pierfrancesco, Bassi, Stefano Maria Magrini, Anna Rita Alitto, Enrica, Ambrosi, Alessandro, Antonelli, Cynthia, Aristei, Michele, Barbieri, Franco, Bardari, Lilia, Bardoscia, Salvina, Barra, Sara, Bartoncini, Umberto, Basso, Carlotta, Becherini, Rita, Bellavita, Franco, Bergamaschi, Stefania, Berlingheri, Berruti, Alfredo, Marco, Borghesi, Roberto, Bortolus, Valentina, Borzillo, Davide, Bosetti, Giuseppe, Bove, Pierluigi, Bove, Maurizio, Brausi, Alessio, Bruni, Giorgio, Bruno, Eugenio, Brunocilla, Alberto, Buffoli, BUGLIONE DI MONALE E BASTIA, Michela, Consuelo, Buttigliero, Giovanni, Cacciamani, Michela, Caldiroli, Giuseppe, Cardo, Giorgio, Carmignani, Giuseppe, Carrieri, Emanuele, Castelli, Elisabetta, Castrezzati, Gianpiero, Catalano, Susanna, Cattarino, Francesco, Catucci, Francolini Dario Cavallini, Ofelia, Ceccarini, Antonio, Celia, Francesco, Chiancone, Tommaso, Chini, Claudia, Cianci, Antonio, Cisternino, Devis, Collura, Franco, Corbella, Matteo, Corinti, Paolo, Corsi, Fiorenza, Cortese, Luigi, Corti, Cosimo de Nunzio, Olga, Cristiano, Rolando, M D'Angelillo, Luigi Da Pozzo, Daniele, D'Agostino, Carolina, D'Elia, Matteo, Dandrea, Michele De Angelis, Paolo De Angelis, Ottavio De Cobelli, Bernardino De Concilio, Antonello De Lisa, Stefano De Luca, Agostina De Stefani, Chiara Lucrezia Deantoni, Esposti Claudio Degli, Anna, Destito, Beatrice, Detti, Nadia Di Muzio, Andrea Di Stasio, Calogero Di Stefano, Danilo Di Trapani, Giuseppe, Difino, Sara, Falivene, Giuseppe, Farullo, Paolo, Fedelini, Ilaria, Ferrari, Francesco, Ferrau, Matteo, Ferro, Andrei, Fodor, Francesco, Fontanta, Francesco, Francesca, Giulio, Francolini, Paolo, Frata, Giovanni, Frezza, Pietro, Gabriele, Maria, Galeandro, Elisabetta, Garibaldi, Pietro Giovanni Gennari, Alessandro, Gentilucci, Alessandro, Giacobbe, Laura, Giussani, Giuseppe, Giusti, Paolo, Gontero, Alessia, Guarneri, Cesare, Guida, Alberto, Gurioli, Dorijan, Huqi, Ciro, Imbimbo, Gianluca, Ingrosso, Cinzia, Iotti, Corrado, Italia, Pierdaniele La Mattina, Enza, Lamanna, Luciana, Lastrucci, Grazia, Lazzari, Fabiola, Liberale, Giovanni, Liguori, Roberto, Lisi, Frank, Lohr, Riccardo, Lombardo, Jon A, J Lovisolo, Giuseppe Mario Ludovico, Nicola, Macchione, Francesca, Maggio, Michele, Malizia, Gianluca, Manasse, Giovanni, Mandoliti, Giovanna, Mantini, Luigi, Marafioti, Luisa, Marciello, Alberto Mario Marconi, Antonietta, Martilotta, Salvino, Marzano, Stefano, Masciullo, Gloria, Maso, Adele, Massenzo, Ercole, Mazzeo, Luigi, Mearini, Serena, Medoro, Rosa, Molè, Giorgio, Monesi, Emanuele, Montanari, Franco, Montefiore, Giampaolo, Montesi, Giuseppe, Morgia, Gregorio, Moro, Giorgio, Muscas, Daniela, Musio, Paolo, Muto, Giovanni, Muzzonigro, Giorgio, Napodano, Carlo Luigi Augusto Negro, Mattia, Nidini, Maria, Ntreta, Marco, Orsatti, Carmela, Palazzolo, Isabella, Palumbo, Alessandro, Parisi, Paolo, Parma, Nicola, Pavan, Martina, Pericolini, Francesco, Pinto, Antonio, Pistone, Valerio, Pizzuti, Angelo, Platania, Caterina, Polli, Giorgio, Pomara, Elisabetta, Ponti, Antonio Benito Porcaro, Francesco, Porpiglia, Dario, Pugliese, Armin, Pycha, Giuseppe, Raguso, Andrea, Rampini, Donato Franco Randone, Valentina, Roboldi, Marco, Roscigno, Maria Paola Ruggieri, Giuseppe, Ruoppo, Roberto, Sanseverino, Anna, Santacaterina, Michele, Santarsieri, Riccardo, Santoni, Sarah, Scagliarini, Giorgio Vittorio Scagliotti, Mauro, Scanzi, Marcello, Scarcia, Riccardo, Schiavina, Alessandro, Sciarra, Carmine, Sciorio, Tindaro, Scolaro, Salvatore, Scuzzarella, Oscar, Selvaggio, Armando, Serao, Sergio, Serni, Marco Andrea Signor, Mauro, Silvani, Giovanni, Silvano, Franco, Silvestris, Simeone, Claudio, Valeria, Simone, Girolamo, Spagnoletti, Matteo Giulio Spinelli, Luigi, Squillace, Vincenzo, Tombolini, Mariastella, Toninelli, Triggiani, Luca, Alberto, Trinchieri, Luca Eolo Trodella, Lucio, Trodella, Carlo, Trombetta, Lidia, Tronnolone, Marcello, Tucci, Daniele, Urzì, Riccardo, Valdagni, Maurizio, Valeriani, Maurizio, Vanoli, Elisabetta, Vitali, Alessandro, Volpe, Stefano, Zaramella, Guglielmo, Zeccolini, Giampaolo, Zini, Porreca, Angelo, Noale, Marianna, Artibani, Walter, Bassi, Pier Francesco, Bertoni, Filippo, Bracarda, Sergio, Conti, Giario Natale, Corvò, Renzo, Gacci, Mauro, Graziotti, Pierpaolo, Magrini, Stefano Maria, Mirone, Vincenzo, Montironi, Rodolfo, Muto, Giovanni, Pecoraro, Stefano, Ricardi, Umberto, Russi, Elvio, Tubaro, Andrea, Zagonel, Vittorina, Crepaldi, Gaetano, Maggi, Stefania, Gaetano, Crepaldi, Umberto, Basso, Luigi, Corti, D'Agostino, Daniele, Matteo, Dandrea, Davide, Bosetti, Gianpiero, Catalano, Ottavio, De Cobelli, Lucrezia, Deantoni Chiara, Nadia, Di Muzio, Ferro, Matteo, Andrei, Fodor, Pierdaniele, La Mattina, Emanuele, Montanari, Barbieri, Michele, Valentina, Borzillo, Chiancone, Francesco, Sara, Falivene, Paolo, Fedelini, Imbimbo, Ciro, Paolo, Muto, Sarah, Scagliarini, Giovanni, Muzzonigro, Enrica, Ambrosi, Alessandro, Antonelli, Lilia, Bardoscia, Stefania, Berlingheri, Alfredo, Berruti, Alberto, Buffoli, Michela, Buglione, Mauro, Scanzi, Elisabetta, Castrezzati, Paolo, Frata, Giulio, Francolini, Beatrice, Detti, Tommaso, Chini, Carlotta, Becherini, Olga, Cristiano, Cesare, Guida, Sara, Bartoncini, Consuelo, Buttigliero, Emanuele, Castelli, Devis, Collura, Stefano, De Luca, Pietro, Gabriele, Elisabetta, Garibaldi, Alessandro, Giacobbe, Paolo, Gontero, Alessia, Guarneri, Alberto, Gurioli, Francesco, Porpiglia, Franco, Randone Donato, Vittorio, Scagliotti Giorgio, Cynthia, Aristei, Rita, Bellavita, Isabella, Palumbo, Franco, Bardari, Augusto, Negro Carlo Luigi, Franco, Bergamaschi, Maria, Galeandro, Cinzia, Iotti, Giuseppe, Raguso, Paola, Ruggieri Maria, Giuseppe, Ruoppo, Marco, Borghesi, Eugenio, Brunocilla, Claudio, Degli Esposti, Giovanni, Frezza, Michele, Malizia, Maria, Ntreta, Alessandro, Parisi, Riccardo, Schiavina, Roberto, Bortolu, Giuseppe, Bove, Antonio, Cisternino, Carrieri, Giuseppe, Giuseppe, Difino, Oscar, Selvaggio, Maurizio, Brausi, Alessio, Bruni, Frank, Lohr, Ercole, Mazzeo, Enza, Lamanna, Calogero, Di Stefano, Giorgio, Bruno, Michela, Caldiroli, Ilaria, Ferrari, Laura, Giussani, Lovisolo Jon, A. J., Mario, Marconi Alberto, Giuseppe, Cardo, Mario, Ludovico Giuseppe, Marcello, Scarcia, Giorgio, Carmignani, Salvina, Barra, Dario, Cavallini Francolini, Franco, Corbella, Ofelia, Ceccarini, Luigi, Da Pozzo, Agostina, De Stefani, Corrado, Italia, Stefano, Masciullo, Valentina, Roboldi, Marco, Roscigno, Antonio, Celia, Bernardino, De Concilio, Claudia, Cianci, Francesco, Francesca, Giorgio, Pomara, Michele, Santarsieri, Fiorenza, Cortese, Andrea, Di Stasio, Franco, Montefiore, Armando, Serao, D'Elia, Carolina, Armin, Pycha, Dorijan, Huqi, Paolo, De Angeli, Nicola, Macchione, Francesco, Fontanta, Giorgio, Monesi, Antonello, De Lisa, Giuseppe, Giusti, Giorgio, Musca, Anna, Destito, Rosa, Molè, Danilo, Di Trapani, Francesco, Ferrau, Carmela, Palazzolo, Angelo, Platania, Anna, Santacaterina, Grazia, Lazzari, Fabiola, Liberale, Gregorio, Moro, Giovanni, Liguori, Nicola, Pavan, Francesca, Maggio, Marco, Orsatti, Giovanni, Mandoliti, Giampaolo, Montesi, Luigi, Marafioti, Antonietta, Martilotta, Adele, Massenzo, Luisa, Marciello, Salvino, Marzano, Caterina, Polli, Gloria, Maso, Serena, Medoro, Giuseppe, Morgia, Napodano, Giorgio, Pistone, Antonio, Roberto, Sanseverino, Mattia, Nidini, Paolo, Parma, Valerio, Pizzuti, Sciorio, Carmine, Scuzzarella, Salvatore, Tindaro, Scolaro, Porreca A, Noale M, Artibani W, Bassi PF, Bertoni F, Bracarda S, Conti GN, Corvò R, Gacci M, Graziotti P, Magrini SM, Mirone V, Montironi R, Muto G, Pecoraro S, Ricardi U, Russi E, Tubaro A, Zagonel V, Crepaldi G, Maggi S, Crepaldi G, Maggi S, Noale M, Porreca A, Artibani W, Bassi P, Bracarda S, Conti GN, Corvò R, Graziotti P, Russi E, Mirone V, Montironi R, Bertoni F, Gacci M, Magrini SM, Muto G, Pecoraro S, Ricardi U, Tubaro A, Zagonel V, Alitto AR, Ambrosi E, Antonelli A, Aristei C, Barbieri M, Bardari F, Bardoscia L, Barra S, Bartoncini S, Basso U, Becherini C, Bellavita R, Bergamaschi F, Berlingheri S, Berruti A, Borghesi M, Bortolus R, Borzillo V, Bosetti D, Bove G, Bove P, Brausi M, Bruni A, Bruno G, Brunocilla E, Buffoli A, Buglione M, Buttigliero C, Cacciamani G, Caldiroli M, Cardo G, Carmignani G, Carrieri G, Castelli E, Castrezzati E, Catalano G, Cattarino S, Catucci F, Cavallini FD, Ceccarini O, Celia A, Chiancone F, Chini T, Cianci C, Cisternino A, Collura D, Corbella F, Corinti M, Corsi P, Cortese F, Corti L, de Nunzio C, Cristiano O, D'Angelillo RM, Da Pozzo L, D'agostino D, D'Elia C, Dandrea M, De Angelis M, De Angelis P, De Cobelli O, De Concilio B, De Lisa A, De Luca S, De Stefani A, Deantoni CL, Degli EC, Destito A, Detti B, Di Muzio N, Di Stasio A, Di Stefano C, Di Trapani D, Difino G, Falivene S, Farullo G, Fedelini P, Ferrari I, Ferrau F, Ferro M, Fodor A, Fontanta F, Francesca F, Francolini G, Frata P, Frezza G, Gabriele P, Galeandro M, Garibaldi E, Gennari PG, Gentilucci A, Giacobbe A, Giussani L, Giusti G, Gontero P, Guarneri A, Guida C, Gurioli A, Huqi D, Imbimbo C, Ingrosso G, Iotti C, Italia C, La Mattina P, Lamanna E, Lastrucci L, Lazzari G, Liberale F, Liguori G, Lisi R, Lohr F, Lombardo R, Lovisolo JAJ, Ludovico GM, Macchione N, Maggio F, Malizia M, Manasse G, Mandoliti G, Mantini G, Marafioti L, Marciello L, Marconi AM, Martilotta A, Marzano S, Masciullo S, Maso G, Massenzo A, Mazzeo E, Mearini L, Medoro S, Molè R, Monesi G, Montanari E, Montefiore F, Montesi G, Morgia G, Moro G, Muscas G, Musio D, Muto P, Muzzonigro G, Napodano G, Negro CLA, Nidini M, Ntreta M, Orsatti M, Palazzolo C, Palumbo I, Parisi A, Parma P, Pavan N, Pericolini M, Pinto F, Pistone A, Pizzuti V, Platania A, Polli C, Pomara G, Ponti E, Porcaro AB, Porpiglia F, Pugliese D, Pycha A, Raguso G, Rampini A, Randone DF, Roboldi V, Roscigno M, Ruggieri MP, Ruoppo G, Sanseverino R, Santacaterina A, Santarsieri M, Santoni R, Scagliarini S, Scagliotti GV, Scanzi M, Scarcia M, Schiavina R, Sciarra A, Sciorio C, Scolaro T, Scuzzarella S, Selvaggio O, Serao A, Serni S, Signor MA, Silvani M, Silvano G, Silvestris F, Simeone C, Simone V, Spagnoletti G, Spinelli MG, Squillace L, Tombolini V, Toninelli M, Triggiani L, Trinchieri A, Trodella LE, Trodella L, Trombetta C, Tronnolone L, Tucci M, Urzì D, Valdagni R, Valeriani M, Vanoli M, Vitali E, Volpe A, Zaramella S, Zeccolini G, Zini G, Porreca, A., Noale, M., Artibani, W., Bassi, P. F., Bertoni, F., Bracarda, S., Conti, G. N., Corvo, R., Gacci, M., Graziotti, P., Magrini, S. M., Mirone, V., Montironi, R., Muto, G., Pecoraro, S., Ricardi, U., Russi, E., Tubaro, A., Zagonel, V., Crepaldi, G., Maggi, S., Alitto, A. R., Ambrosi, E., Antonelli, A., Aristei, C., Barbieri, M., Bardari, F., Bardoscia, L., Barra, S., Bartoncini, S., Basso, U., Becherini, C., Bellavita, R., Bergamaschi, F., Berlingheri, S., Berruti, A., Borghesi, M., Bortolus, R., Borzillo, V., Bosetti, D., Bove, G., Bove, P., Maurizio, B., Alessio, B., Giorgio, B., Eugenio, B., Alberto, B., Michela, B., Consuelo, B., Giovanni, C., Michela, C., Giuseppe, C., Giorgio, C., Emanuele, C., Elisabetta, C., Gianpiero, C., Susanna, C., Catucci, F., Dario, C. F., Ofelia, C., Antonio, C., Francesco, C., Tommaso, C., Claudia, C., Devis, C., Franco, C., Matteo, C., Paolo, C., Fiorenza, C., Luigi, C., Cosimo, N., Cristiano, O., D'Angelillo, R. M., Da Pozzo, L., D'Agostino, D., D'Elia, C., Dandrea, M., De Angelis, M., De Angelis, P., De Cobelli, O., De Concilio, B., De Lisa, A., De Luca, S., De Stefani, A., Deantoni, C. L., Degli, E. C., Destito, A., Detti, B., Di Muzio, N., Di Stasio, A., Di Stefano, C., Di Trapani, D., Difino, G., Falivene, S., Farullo, G., Fedelini, P., Ferrari, I., Ferrau, F., Ferro, M., Fodor, A., Fontanta, F., Francesca, F., Francolini, G., Frata, P., Frezza, G., Gabriele, P., Galeandro, M., Garibaldi, E., Gennari, P. G., Gentilucci, A., Giacobbe, A., Giussani, L., Giusti, G., Gontero, P., Guarneri, A., Guida, C., Gurioli, A., Huqi, D., Imbimbo, C., Ingrosso, G., Iotti, C., Italia, C., La Mattina, P., Lamanna, E., Lastrucci, L., Lazzari, G., Liberale, F., Liguori, G., Lisi, R., Lohr, F., Lombardo, R., Lovisolo, J. A. J., Ludovico, G. M., Macchione, N., Maggio, F., Malizia, M., Manasse, G., Mandoliti, G., Mantini, G., Marafioti, L., Marciello, L., Marconi, A. M., Martilotta, A., Marzano, S., Masciullo, S., Maso, G., Massenzo, A., Mazzeo, E., Mearini, L., Medoro, S., Mole, R., Monesi, G., Montanari, E., Montefiore, F., Montesi, G., Morgia, G., Moro, G., Muscas, G., Musio, D., Muto, P., Muzzonigro, G., Napodano, G., Negro, C. L. A., Nidini, M., Ntreta, M., Orsatti, M., Palazzolo, C., Palumbo, I., Parisi, A., Parma, P., Pavan, N., Pericolini, M., Pinto, F., Pistone, A., Pizzuti, V., Platania, A., Polli, C., Pomara, G., Ponti, E., Porcaro, A. B., Porpiglia, F., Pugliese, D., Pycha, A., Raguso, G., Rampini, A., Randone, D. F., Roboldi, V., Roscigno, M., Ruggieri, M. P., Ruoppo, G., Sanseverino, R., Santacaterina, A., Santarsieri, M., Santoni, R., Scagliarini, S., Scagliotti, G. V., Scanzi, M., Scarcia, M., Schiavina, R., Sciarra, A., Sciorio, C., Scolaro, T., Scuzzarella, S., Selvaggio, O., Serao, A., Serni, S., Signor, M. A., Silvani, M., Silvano, G., Silvestris, F., Simeone, C., Simone, V., Spagnoletti, G., Spinelli, M. G., Squillace, L., Tombolini, V., Toninelli, M., Triggiani, L., Trinchieri, A., Trodella, L. E., Trodella, L., Trombetta, C., Tronnolone, L., Tucci, M., Urzi, D., Valdagni, R., Valeriani, M., Vanoli, M., Vitali, E., Volpe, A., Zaramella, S., Zeccolini, G., Zini, G., Porreca, A, Noale, M, Artibani, W, Bassi, P, Bertoni, F, Bracarda, S, Conti, G, Corvò, R, Gacci, M, Graziotti, P, Magrini, S, Mirone, V, Montironi, R, Muto, G, Pecoraro, S, Ricardi, U, Russi, E, Tubaro, A, Zagonel, V, Crepaldi, G, Maggi, S, and Da Pozzo, L

Subjects
Male, 030232 urology & nephrology, Severity of Illness Index, Prostate cancer, 0302 clinical medicine, Quality of life, Activities of Daily Living, Diagnosis, Medicine, Age Factor, Prospective Studies, Prospective cohort study, Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA, Age Factors, Pros-IT CNR study, General Medicine, Health Survey, Middle Aged, Neoadjuvant Therapy, 3. Good health, Italy, 030220 oncology & carcinogenesis, lcsh:R858-859.7, Regression Analysis, Public Health, Human, Diagnosi, prostate cancer, survival, quality of life, medicine.medical_specialty, lcsh:Computer applications to medicine. Medical informatics, Regression Analysi, 03 medical and health sciences, Percutaneous Coronary Intervention, Internal medicine, Severity of illness, Humans, Aged, Cancer staging, business.industry, Research, Environmental and Occupational Health, Public Health, Environmental and Occupational Health, Prostatic Neoplasms, Cancer, medicine.disease, Health Surveys, Comorbidity, Quality of Life, Prospective Studie, Settore MED/24, Prostatic Neoplasm, business, Sexual function
Abstract

Background The National Research Council (CNR) prostate cancer monitoring project in Italy (Pros-IT CNR) is an observational, prospective, ongoing, multicentre study aiming to monitor a sample of Italian males diagnosed as new cases of prostate cancer. The present study aims to present data on the quality of life at time prostate cancer is diagnosed. Methods One thousand seven hundred five patients were enrolled. Quality of life is evaluated at the time cancer was diagnosed and at subsequent assessments via the Italian version of the University of California Los Angeles-Prostate Cancer Index (UCLA-PCI) and the Short Form Health Survey (SF-12). Results At diagnosis, lower scores on the physical component of the SF-12 were associated to older ages, obesity and the presence of 3+ moderate/severe comorbidities. Lower scores on the mental component were associated to younger ages, the presence of 3+ moderate/severe comorbidities and a T-score higher than one. Urinary and bowel functions according to UCLA-PCI were generally good. Almost 5% of the sample reported using at least one safety pad daily to control urinary loss; less than 3% reported moderate/severe problems attributable to bowel functions, and sexual function was a moderate/severe problem for 26.7%. Diabetes, 3+ moderate/severe comorbidities, T2 or T3-T4 categories and a Gleason score of eight or more were significantly associated with lower sexual function scores at diagnosis. Conclusions Data collected by the Pros-IT CNR study have clarified the baseline status of newly diagnosed prostate cancer patients. A comprehensive assessment of quality of life will allow to objectively evaluate outcomes of different profile of care.

Published
2018

167. Letter to the Editor regarding ESTRO-ASTRO guidelines on lung cancer radiotherapy during COVID-19 pandemic

Author

Filippo Alongi, Stefano Maria Magrini, Lorenzo Livi, Paolo Borghetti, Marta Scorsetti, Stefano Arcangeli, Elvio G. Russi, Renzo Corvò, Barbara Alicja Jereczek-Fossa, Stefano Vagge, Michela Buglione, Andrea Riccardo Filippi, Magrini, S, Borghetti, P, Filippi, A, Scorsetti, M, Jereczek-Fossa, B, Corvò, R, Arcangeli, S, Vagge, S, Russi, E, Alongi, F, Livi, L, and Buglione, M

Subjects
medicine.medical_specialty, Letter to the editor, Coronavirus disease 2019 (COVID-19), business.industry, medicine.medical_treatment, Hematology, medicine.disease, Radiation therapy, Oncology, Radiology Nuclear Medicine and imaging, Radiation oncology, Pandemic, medicine, Covid-19, Radiotherapy, Radiology, Nuclear Medicine and imaging, Medical physics, business, Lung cancer, Coronavirus Infections, Cancer staging
Published
2020
Full Text
View/download PDF

168. Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy

Author

Giulia Marvaso, R. Mazzola, Andrea Riccardo Filippi, Luciana Caravatta, Stefano Maria Magrini, Filippo Alongi, Stefano Pergolizzi, Isabella Palumbo, Liliana Belgioia, Michela Buglione, Domenico Genovesi, Carlotta Becherini, Alessandro Sindoni, Umberto Ricardi, Carlo Greco, Lorenzo Livi, Sara Ramella, Icro Meattini, Rolando Maria D'Angelillo, Michele Fiore, Marco Trovo, Stefano Arcangeli, Elvio G. Russi, Cynthia Aristei, Vincenzo Valentini, Anna Merlotti, Barbara Alicja Jereczek-Fossa, Renzo Corvò, Arcangeli, S, Jereczek-Fossa, B, Alongi, F, Aristei, C, Becherini, C, Belgioia, L, Buglione, M, Caravatta, L, D'Angelillo, R, Filippi, A, Fiore, M, Genovesi, D, Greco, C, Livi, L, Magrini, S, Marvaso, G, Mazzola, R, Meattini, I, Merlotti, A, Palumbo, I, Pergolizzi, S, Ramella, S, Ricardi, U, Russi, E, Trovò, M, Sindoni, A, Valentini, V, and Corvò, R

Subjects
0301 basic medicine, Oncology, Radiation-Sensitizing Agents, medicine.medical_specialty, Bevacizumab, medicine.medical_treatment, Settore MED/06, NOVEL SYSTEMIC AGENTS, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Settore MED/36, Humans, Italy, Neoplasms, Treatment Outcome, Chemoradiotherapy, Hematology, Internal medicine, medicine, Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA, Temozolomide, business.industry, Sunitinib, Hematology, Oncology, EFFICACY, medicine.disease, Radiation therapy, 030104 developmental biology, Darolutamide, neoplasms, radiation-sensitizing agents, treatment outcome, chemoradiotherapy, 030220 oncology & carcinogenesis, business, RADIOTHERAPY, medicine.drug, Brain metastasis
Abstract

Over the past century, technologic advances have promoted the evolution of radiation therapy into a precise treatment modality allowing for the maximal administration of dose to tumors while sparing normal tissues. In parallel with this technological maturation, the rapid expansion in understanding the basic biology and heterogeneity of cancer has led to the development of several compounds that target specific pathways. Many of them are in advanced steps of clinical development for combination treatments with radiotherapy, and can be incorporated into radiation oncology practice for a personalized approach to maximize the therapeutic gain. This review describes the rationale for combining novel agents with radiation, and provides an overview of the current landscape focused on treatment efficacy.

Published
2019
Full Text
View/download PDF

169. Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study.

Author

Merlano, M., Russi, E., Benasso, M., Corvò, R., Colantonio, I., Vigna-Taglianti, R., Vigo, V., Bacigalupo, A., Numico, G., Crosetto, N., Gasco, M., Lo Nigro, C., Vitiello, R., Violante, S., and Garrone, O.

Subjects
*CISPLATIN, *HEAD & neck cancer, *SQUAMOUS cell carcinoma, *RADIOTHERAPY, *DRUG therapy, *CETUXIMAB, *FLUOROURACIL, *RADIODERMATITIS
Abstract

Background: Intensification of chemoradiation for advanced head and neck squamous cell carcinoma (HNSCC) is unlikely due to toxicity. Cetuximab combined either with radiotherapy or with chemotherapy showed favourable toxic profile with positive results in both combinations. Therefore, cetuximab could intensify chemoradiation without worsening toxicity. We conducted a phase II study of chemoradiation and cetuximab.Patients and methods: Eligible patients had stage III–IV M0 HNSCC. Treatment consisted of three cycles of cisplatin (20 mg/m2/day × 5 days) and fluorouracil (200 mg/m2/day × 5 days) rapidly alternated to three split courses of radiotherapy up to 70 Gy and concurrent weekly cetuximab. The primary end point of the study was complete response (CR) rate. Secondary end points were toxicity, progression-free survival (PFS) and overall survival (OS).Results: Fourty-five patients were enrolled: median age was 56 years, 38 had stage IV disease and 40 nodal involvement. CR occurred in 32 patients (71%). PFS and OS was 21+ months and 32.6+, respectively. Acute grade 3–4 toxic effects were in the expected range, but grade 3 radiodermatitis occurred in 33 patients.Conclusions: The combination of cetuximab, cisplatin, fluorouracil and radiotherapy leads to a very high proportion of CR and it is feasible with toxic effects similar to those expected by radiochemotherapy. The only unexpected toxicity was skin toxicity: grade 3 radiodermatitis occurred in 73% of the patients. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

170. PO-0942: Post-mastectomy radiotherapy after Immediate versus Two-Stage Breast Reconstruction.

Author

Bonzano, E., Guenzi, M., De La Lande, B., Musat, E., Albert-Dufrois, H., Otz, J., Clément-Zhao, A., Filippi, A.R., Corvò, R., and Poortmans, P.

Subjects
*MAMMAPLASTY, *RADIOTHERAPY
Abstract

E. Bonzano, M. Guenzi, B. De La Lande, E. Musat, H. Albert-Dufrois, J. Otz, A. Clément-Zhao, A.R. Filippi, R. Corvò, P. Poortmans, Poster: Clinical track: Breast PO-0942: Post-mastectomy radiotherapy after Immediate versus Two-Stage Breast Reconstruction. [Extracted from the article]

Published
2020
Full Text
View/download PDF

171. Pros-IT CNR: an Italian prostate cancer monitoring project

Author

Noale, Marianna, Maggi, Stefania, Artibani, Walter, Bassi, Pier Francesco, Bertoni, Filippo, Bracarda, Sergio, Conti, Giario Natale, Corvo', RENZO GIACINTO, Gacci, Mauro, Graziotti, Pierpaolo, Magrini, Stefano Maria, Maurizi Enrici, Riccardo, Mirone, Vincenzo, Montironi, Rodolfo, Muto, Giovanni, Pecoraro, Stefano, Porreca, Angelo, Ricardi, Umberto, Tubaro, Andrea, Zagonel, Vittorina, Zattoni, Filiberto, Crepaldi, Gaetano, Corvò, Renzo, Alitto, Anna Rita, Ambrosi, Enrica, Antonelli, Alessandro, Aristei, Cynthia, Barbieri, Michele, Bardari, Franco, Bardoscia, Lilia, Barra, Salvina, Bartoncini, Sara, Basso, Umberto, Becherini, Carlotta, Bellavita, Rita, Bergamaschi, Franco, Berlingheri, Stefania, Berruti, Alfredo, Borghesi, Marco, Bortolus, Roberto, Borzillo, Valentina, Bosetti, Davide, Bove, Giuseppe, Bove, Pierluigi, Brausi, Maurizio, Bruni, Alessio, Bruno, Giorgio, Brunocilla, Eugenio, Buffoli, Alberto, BUGLIONE DI MONALE E BASTIA, Michela, Buttigliero, Consuelo, Cacciamani, Giovanni, Caldiroli, Michela, Cardo, Giuseppe, Carmignani, Giorgio, Carrieri, Giuseppe, Castelli, Emanuele, Castrezzati, Elisabetta, Catalano, Gianpiero, Cattarino, Susanna, Catucci, Francesco, Cavallini Francolini, Dario, Ceccarini, Ofelia, Celia, Antonio, Chiancone, Francesco, Chini, Tommaso, Cianci, Claudia, Cisternino, Antonio, Collura, Devis, Corbella, Franco, Corinti, Matteo, Corsi, Paolo, Cortese, Fiorenza, Corti, Luigi, de Nunzio, Cosimo, Cristiano, Olga, D'Angelillo, Rolando, Da Pozzo, Luigi, D'Agostino, Daniele, D’Andrea, David, Dandrea, Matteo, De Angelis, Michele, De Cobelli, Ottavio, De Concilio, Bernardino, De Lisa, Antonello, De Luca, Stefano, De Stefani, Agostina, Deantoni, Chiara Lucrezia, Degli Esposti, Claudio, Destito, Anna, Detti, Beatrice, Di Muzio, Nadia, Di Stasio, Andrea, Di Stefano, Calogero, Di Trapani, Danilo, Difino, Giuseppe, Falivene, Sara, Farullo, Giuseppe, Fedelini, Paolo, Ferrari, Ilaria, Ferrau, Francesco, Ferro, Matteo, Fodor, Andrei, Fontana, Francesco, Francesca, Francesco, Giulio, Francolini, Frata, Paolo, Frezza, Giovanni, Gabriele, Pietro, Galeandro, Maria, Garibaldi, Elisabetta, Gennari, Pietro, Gentilucci, Alessandro, Giacobbe, Alessandro, Giussani, Laura, Giusti, Giuseppe, Gontero, Paolo, Guarneri, Alessia, Guida, Cesare, Gurioli, Alberto, Huqi, Dorijan, Imbimbo, Ciro, Ingrosso, Gianluca, Iotti, Cinzia, Italia, Corrado, La Mattina, Pierdaniele, Lamanna, Enza, Lastrucci, Luciana, Lazzari, Grazia, Liberale, Fabiola, Liguori, Giovanni, Lisi, Roberto, Lohr, Frank, Lombardo, Riccardo, Lovisolo, Jon, Ludovico, Giuseppe Mario, Macchione, Nicola, Maggio, Francesca, Malizia, Michele, Manasse, Gianluca, Mandoliti, Giovanni, Mantini, Giovanna, Marafioti, Luigi, Marciello, Luisa, Marconi, Alberto Mario, Martillotta, Antonietta, Marzano, Salvino, Masciullo, Stefano, Maso, Gloria, Massenzo, Adele, Mazzeo, Ercole, Mearini, Luigi, Medoro, Serena, Molè, Rosa, Monesi, Giorgio, Montanari, Emanuele, Montefiore, Franco, Montesi, Giampaolo, Morgia, Giuseppe, Moro, Gregorio, Muscas, Giorgio, Musio, Daniela, Muto, Paolo, Muzzonigro, Giovanni, Napodano, Giorgio, Negro, Carlo Luigi Augusto, Nidini, Mattia, Ntreta, Maria, Orsatti, Marco, Palazzolo, Carmela, Palumbo, Isabella, Parisi, Alessandro, Parma, Paolo, Pavan, Nicola, Pericolini, Martina, Pinto, Francesco, Pistone, Antonio, Pizzuti, Valerio, Platania, Angelo, Polli, Caterina, Pomara, Giorgio, Ponti, Elisabetta, Porcaro, Antonio Benito, Porpiglia, Francesco, Pugliese, Dario, Pycha, Armin, Raguso, Giuseppe, Rampini, Andrea, Randone, Donato Franco, Roscigno, Marco, Ruggieri, Maria Paola, Ruoppo, Giuseppe, Sanseverino, Roberto, Santacaterina, Anna, Santarsieri, Michele, Santoni, Riccardo, Scagliarini, Sarah, Scagliotti, Giorgio Vittorio, Scanzi, Mauro, Scarcia, Marcello, Schiavina, Riccardo, Sciarra, Alessandro, Sciorio, Carmine, Scolaro, Tindaro, Scuzzarella, Salvatore, Selvaggio, Oscar, Serao, Armando, Serni, Sergio, Signor, Marco Andrea, Silvani, Mauro, Silvano, Giovanni, Silvestris, Franco, Simeone, Claudio, Simone, Valeria, Spagnoletti, Girolamo, Spinelli, Matteo Giulio, Squillace, Luigi, Tombolini, Vincenzo, Toninelli, Mariastella, Triggiani, Luca, Trinchieri, Alberto, Trodella, Luca Eolo, Trodella, Lucio, Trombetta, Carlo, Tronnolone, Lidia, Tucci, Marcello, Urzì, Daniele, Valdagni, Riccardo, Valeriani, Maurizio, Vanoli, Maurizio, Vitali, Elisabetta, Zaramella, Stefano, Zeccolini, Guglielmo, Zini, Giampaolo, Marianna Noale, Stefania Maggi, Walter Artibani, Pier Francesco Bassi, Filippo Bertoni, Sergio Bracarda, Giario Natale Conti, Renzo Corvò, Mauro Gacci, Pierpaolo Graziotti, Stefano Maria Magrini, Riccardo Maurizi Enrici, Vincenzo Mirone, Rodolfo Montironi, Giovanni Muto, Stefano Pecoraro, Angelo Porreca, Umberto Ricardi, Andrea Tubaro, Vittorina Zagonel, Filiberto Zattoni, Gaetano Crepaldi, the Pros-IT CNR study group: [.., Marco Borghesi, Eugenio Brunocilla, Riccardo Schiavina, ], Noale, M, Maggi, S, Artibani, W, Bassi, P, Bertoni, F, Bracarda, S, Conti, G, Corvò, R, Gacci, M, Graziotti, P, Magrini, S, Maurizi Enrici, R, Mirone, V, Da Pozzo, L, and Pros-IT CNR study, G, Noale, Marianna, Maggi, Stefania, Artibani, Walter, Bassi, Pier Francesco, Bertoni, Filippo, Bracarda, Sergio, Conti, Giario Natale, Corvò, Renzo, Gacci, Mauro, Graziotti, Pierpaolo, Magrini, Stefano Maria, Maurizi Enrici, Riccardo, Mirone, Vincenzo, Montironi, Rodolfo, Muto, Giovanni, Pecoraro, Stefano, Porreca, Angelo, Ricardi, Umberto, Tubaro, Andrea, Zagonel, Vittorina, Zattoni, Filiberto, Crepaldi, Gaetano, Alitto, Anna Rita, Ambrosi, Enrica, Antonelli, Alessandro, Aristei, Cynthia, Barbieri, Michele, Bardari, Franco, Bardoscia, Lilia, Barra, Salvina, Bartoncini, Sara, Basso, Umberto, Becherini, Carlotta, Bellavita, Rita, Bergamaschi, Franco, Berlingheri, Stefania, Berruti, Alfredo, Borghesi, Marco, Bortolus, Roberto, Borzillo, Valentina, Bosetti, Davide, Bove, Giuseppe, Bove, Pierluigi, Brausi, Maurizio, Bruni, Alessio, Bruno, Giorgio, Brunocilla, Eugenio, Buffoli, Alberto, Buglione, Michela, Buttigliero, Consuelo, Cacciamani, Giovanni, Caldiroli, Michela, Cardo, Giuseppe, Carmignani, Giorgio, Carrieri, Giuseppe, Castelli, Emanuele, Castrezzati, Elisabetta, Catalano, Gianpiero, Cattarino, Susanna, Catucci, Francesco, Cavallini Francolini, Dario, Ceccarini, Ofelia, Celia, Antonio, Chiancone, Francesco, Chini, Tommaso, Cianci, Claudia, Cisternino, Antonio, Collura, Devi, Corbella, Franco, Corinti, Matteo, Corsi, Paolo, Cortese, Fiorenza, Corti, Luigi, de Nunzio, Cosimo, Cristiano, Olga, D’Angelillo, Rolando, Da Pozzo, Luigi, D’Agostino, Daniele, D’Andrea, David, Dandrea, Matteo, De Angelis, Michele, De Cobelli, Ottavio, De Concilio, Bernardino, De Lisa, Antonello, De Luca, Stefano, De Stefani, Agostina, Deantoni, Chiara Lucrezia, Degli Esposti, Claudio, Destito, Anna, Detti, Beatrice, Di Muzio, Nadia, Di Stasio, Andrea, Di Stefano, Calogero, Di Trapani, Danilo, Difino, Giuseppe, Falivene, Sara, Farullo, Giuseppe, Fedelini, Paolo, Ferrari, Ilaria, Ferrau, Francesco, Ferro, Matteo, Fodor, Andrei, Fontana, Francesco, Francesca, Francesco, Giulio, Francolini, Frata, Paolo, Frezza, Giovanni, Gabriele, Pietro, Galeandro, Maria, Garibaldi, Elisabetta, Gennari, Pietro, Gentilucci, Alessandro, Giacobbe, Alessandro, Giussani, Laura, Giusti, Giuseppe, Gontero, Paolo, Guarneri, Alessia, Guida, Cesare, Gurioli, Alberto, Huqi, Dorijan, Imbimbo, Ciro, Ingrosso, Gianluca, Iotti, Cinzia, Italia, Corrado, La Mattina, Pierdaniele, Lamanna, Enza, Lastrucci, Luciana, Lazzari, Grazia, Liberale, Fabiola, Liguori, Giovanni, Lisi, Roberto, Lohr, Frank, Lombardo, Riccardo, Lovisolo, Jon, Ludovico, Giuseppe Mario, Macchione, Nicola, Maggio, Francesca, Malizia, Michele, Manasse, Gianluca, Mandoliti, Giovanni, Mantini, Giovanna, Marafioti, Luigi, Marciello, Luisa, Marconi, Alberto Mario, Martillotta, Antonietta, Marzano, Salvino, Masciullo, Stefano, Maso, Gloria, Massenzo, Adele, Mazzeo, Ercole, Mearini, Luigi, Medoro, Serena, Molè, Rosa, Monesi, Giorgio, Montanari, Emanuele, Montefiore, Franco, Montesi, Giampaolo, Morgia, Giuseppe, Moro, Gregorio, Muscas, Giorgio, Musio, Daniela, Muto, Paolo, Muzzonigro, Giovanni, Napodano, Giorgio, Negro, Carlo Luigi Augusto, Nidini, Mattia, Ntreta, Maria, Orsatti, Marco, Palazzolo, Carmela, Palumbo, Isabella, Parisi, Alessandro, Parma, Paolo, Pavan, Nicola, Pericolini, Martina, Pinto, Francesco, Pistone, Antonio, Pizzuti, Valerio, Platania, Angelo, Polli, Caterina, Pomara, Giorgio, Ponti, Elisabetta, Porcaro, Antonio Benito, Porpiglia, Francesco, Pugliese, Dario, Pycha, Armin, Raguso, Giuseppe, Rampini, Andrea, Randone, Donato Franco, Roscigno, Marco, Ruggieri, Maria Paola, Ruoppo, Giuseppe, Sanseverino, Roberto, Santacaterina, Anna, Santarsieri, Michele, Santoni, Riccardo, Scagliarini, Sarah, Scagliotti, Giorgio Vittorio, Scanzi, Mauro, Scarcia, Marcello, Schiavina, Riccardo, Sciarra, Alessandro, Sciorio, Carmine, Scolaro, Tindaro, Scuzzarella, Salvatore, Selvaggio, Oscar, Serao, Armando, Serni, Sergio, Signor, Marco Andrea, Silvani, Mauro, Silvano, Giovanni, Silvestris, Franco, Simeone, Claudio, Simone, Valeria, Spagnoletti, Girolamo, Spinelli, Matteo Giulio, Squillace, Luigi, Tombolini, Vincenzo, Toninelli, Mariastella, Triggiani, Luca, Trinchieri, Alberto, Trodella, Luca Eolo, Trodella, Lucio, Trombetta, Carlo, Tronnolone, Lidia, Tucci, Marcello, Urzì, Daniele, Valdagni, Riccardo, Valeriani, Maurizio, Vanoli, Maurizio, Vitali, Elisabetta, Zaramella, Stefano, Zeccolini, Guglielmo, Zini, Giampaolo, Noale, M., Maggi, S., Artibani, W., Bassi, P. F., Bertoni, F., Bracarda, S., Conti, G. N., Corvo, R., Gacci, M., Graziotti, P., Magrini, S. M., Maurizi Enrici, R., Mirone, V., Montironi, R., Muto, G., Pecoraro, S., Porreca, A., Ricardi, U., Tubaro, A., Zagonel, V., Zattoni, F., Crepaldi, G., Alitto, A. R., Ambrosi, E., Antonelli, A., Aristei, C., Barbieri, M., Bardari, F., Bardoscia, L., Barra, S., Bartoncini, S., Basso, U., Becherini, C., Bellavita, R., Bergamaschi, F., Berlingheri, S., Berruti, A., Borghesi, M., Bortolus, R., Borzillo, V., Bosetti, D., Bove, G., Bove, P., Brausi, M., Bruni, A., Bruno, G., Brunocilla, E., Buffoli, A., Buglione, M., Buttigliero, C., Cacciamani, G., Caldiroli, M., Cardo, G., Carmignani, G., Carrieri, G., Castelli, E., Castrezzati, E., Catalano, G., Cattarino, S., Catucci, F., Cavallini Francolini, D., Ceccarini, O., Celia, A., Chiancone, F., Chini, T., Cianci, C., Cisternino, A., Collura, D., Corbella, F., Corinti, M., Corsi, P., Cortese, F., Corti, L., de Nunzio, C., Cristiano, O., D'Angelillo, R., Da Pozzo, L., D'Agostino, D., D'Andrea, D., Dandrea, M., De Angelis, M., De Cobelli, O., De Concilio, B., De Lisa, A., De Luca, S., De Stefani, A., Deantoni, C. L., Degli Esposti, C., Destito, A., Detti, B., Di Muzio, N., Di Stasio, A., Di Stefano, C., Di Trapani, D., Difino, G., Falivene, S., Farullo, G., Fedelini, P., Ferrari, I., Ferrau, F., Ferro, M., Fodor, A., Fontana, F., Francesca, F., Giulio, F., Frata, P., Frezza, G., Gabriele, P., Galeandro, M., Garibaldi, E., Gennari, P., Gentilucci, A., Giacobbe, A., Giussani, L., Giusti, G., Gontero, P., Guarneri, A., Guida, C., Gurioli, A., Huqi, D., Imbimbo, C., Ingrosso, G., Iotti, C., Italia, C., La Mattina, P., Lamanna, E., Lastrucci, L., Lazzari, G., Liberale, F., Liguori, G., Lisi, R., Lohr, F., Lombardo, R., Lovisolo, J., Ludovico, G. M., Macchione, N., Maggio, F., Malizia, M., Manasse, G., Mandoliti, G., Mantini, G., Marafioti, L., Marciello, L., Marconi, A. M., Martillotta, A., Marzano, S., Masciullo, S., Maso, G., Massenzo, A., Mazzeo, E., Mearini, L., Medoro, S., Mole, R., Monesi, G., Montanari, E., Montefiore, F., Montesi, G., Morgia, G., Moro, G., Muscas, G., Musio, D., Muto, P., Muzzonigro, G., Napodano, G., Negro, C. L. A., Nidini, M., Ntreta, M., Orsatti, M., Palazzolo, C., Palumbo, I., Parisi, A., Parma, P., Pavan, N., Pericolini, M., Pinto, F., Pistone, A., Pizzuti, V., Platania, A., Polli, C., Pomara, G., Ponti, E., Porcaro, A. B., Porpiglia, F., Pugliese, D., Pycha, A., Raguso, G., Rampini, A., Randone, D. F., Roscigno, M., Ruggieri, M. P., Ruoppo, G., Sanseverino, R., Santacaterina, A., Santarsieri, M., Santoni, R., Scagliarini, S., Scagliotti, G. V., Scanzi, M., Scarcia, M., Schiavina, R., Sciarra, A., Sciorio, C., Scolaro, T., Scuzzarella, S., Selvaggio, O., Serao, A., Serni, S., Signor, M. A., Silvani, M., Silvano, G., Silvestris, F., Simeone, C., Simone, V., Spagnoletti, G., Spinelli, M. G., Squillace, L., Tombolini, V., Toninelli, M., Triggiani, L., Trinchieri, A., Trodella, L. E., Trodella, L., Trombetta, C., Tronnolone, L., Tucci, M., Urzi, D., Valdagni, R., Valeriani, M., Vanoli, M., Vitali, E., Zaramella, S., Zeccolini, G., and Zini, G.

Subjects
Italian UCLA Cancer Index, Prostate cancer, Prostate cancer treatments, Quality of life, SF-12 Scale, Adult, Aged, Biopsy, Disease Management, Health Status, Humans, Italy, Male, Middle Aged, Neoplasm Staging, Prospective Studies, Prostatic Neoplasms, Quality of Life, Aging, Geriatrics and Gerontology, medicine.medical_specialty, 03 medical and health sciences, 0302 clinical medicine, medicine, 030212 general & internal medicine, Risk factor, Disease management (health), Prospective cohort study, Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA, Cancer staging, business.industry, medicine.disease, Clinical trial, Prostate cancer, Monitoring, Survival, Outcomes, Settore MED/24, Prostate cancer treatment, 030220 oncology & carcinogenesis, Family medicine, Physical therapy, Observational study, business
Abstract

Aims: The Pros-IT CNR project aims to monitor a sample of Italian males ≥18years of age who have been diagnosed in the participating centers with incident prostate cancer, by analyzing their clinical features, treatment protocols and outcome results in relation to quality of life. Methods: Pros-IT CNR is an observational, prospective, multicenter study. The National Research Council (CNR), Neuroscience Institute, Aging Branch (Padua) is the promoting center. Ninety-seven Italian centers located throughout Italy were involved. The field study began in September 1, 2014. Subjects eligible were diagnosed with biopsy-verified prostate cancer, naïve. A sample size of 1500 patients was contemplated. A baseline assessment including anamnestic data, clinical history, risk factors, the initial diagnosis, cancer staging information and quality of life (Italian UCLA Prostate Cancer Index; SF-12 Scale) was completed. Six months after the initial diagnosis, a second assessment evaluating the patient’s health status, the treatment carried out, and the quality of life will be made. A third assessment, evaluating the treatment follow-up and the quality of life, will be made 12months after the initial diagnosis. The 4th, 5th, 6th and 7th assessments, similar to the third, will be completed 24, 36, 48 and 60months after the initial diagnosis, respectively, and will include also a Food Frequency Questionnaire and the Physical Activity Scale for the Elderly. Discussion: The study will provide information on patients’ quality of life and its variations over time in relation to the treatments received for the prostate cancer.

Published
2017
Full Text
View/download PDF

173. Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment toxicity

Author

Anna Merlotti, Filippo Alongi, Domenico Genovesi, Andrea Riccardo Filippi, Cynthia Aristei, Stefano Maria Magrini, Rolando Maria D'Angelillo, Vincenzo Valentini, Liliana Belgioia, Renzo Corvò, Icro Meattini, Carlotta Becherini, Marco Trovo, Stefano Arcangeli, Giulia Marvaso, Umberto Ricardi, Elvio G. Russi, Lorenzo Livi, Luciana Caravatta, Stefano Pergolizzi, Rosario Mazzola, Alessandro Sindoni, Barbara Alicia Jereczek-Fossa, Sara Ramella, Michela Buglione, Michele Fiore, Carlo Greco, Isabella Palumbo, Arcangeli, S, Jereczek-Fossa, B, Alongi, F, Aristei, C, Becherini, C, Belgioia, L, Buglione, M, Caravatta, L, D'Angelillo, R, Filippi, A, Fiore, M, Genovesi, D, Greco, C, Livi, L, Magrini, S, Marvaso, G, Mazzola, R, Meattini, I, Merlotti, A, Palumbo, I, Pergolizzi, S, Ramella, S, Ricardi, U, Russi, E, Trovò, M, Sindoni, A, Valentini, V, and Corvò, R

Subjects
Oncology, medicine.medical_specialty, Radiation-Sensitizing Agents, medicine.medical_treatment, Context (language use), Novel Sytemc Agent, Settore MED/06, Therapeutic index, Settore MED/36, Internal medicine, Neoplasms, medicine, Radiotherapy, Systemic compounds, Toxicity, Humans, Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA, Clinical Oncology, Hematology, business.industry, Chemoradiotherapy, Radiotherapy, Systemic compounds, Toxicity, Hematology, Oncology, Clinical trial, Radiation therapy, Italy, Treatment Outcome, Systemic compound, business
Abstract

Clinical development and use of novel systemic agents in combination with radiotherapy (RT) is at nowadays most advanced in the field of treatment of solid tumors. Although for many of these substances preclinical studies provide sufficient evidences on their principal capability to enhance radiation effects, the majority of them have not been investigated in even phase I clinical trials for safety in the context of RT. In clinical practice, unexpected acute and late side effects may emerge especially in combination with RT. As a matter of fact, despite combined modality treatment holds potential for enhancing the therapeutic ratio, some concerns are raised from the lack of high-quality clinical data to guide the care of patients who are treated with novel compounds in conjunction with RT. The aim of this review is to provide, from a radio-oncological point of view, an overview of the most advanced combined treatment concepts for solid tumors focusing on treatment toxicity.

Published
2019

182. PH-0038: RT and concomitant CDDP vs cetuximab for head and neck cancer: long term outcomes of a randomized PH. II trial.

Author

Tomasini, D., Maddalo, M., Borghetti, P., Corvò, R., Bonomo, P., Petrucci, A., Paiar, F., Lastrucci, L., Bonù, M.L., Greco, D., Costa, L., Pegurri, L., Triggiani, L., Belgioia, L., Desideri, I., Grisanti, S., Buglione, M., and Magrini, S.M.

Subjects
*HEAD & neck cancer, *CETUXIMAB
Abstract

II trial D. Tomasini, M. Maddalo, P. Borghetti, R. Corvò, P. Bonomo, A. Petrucci, F. Paiar, L. Lastrucci, M.L. Bonù, D. Greco, L. Costa, L. Pegurri, L. Triggiani, L. Belgioia, I. Desideri, S. Grisanti, M. Buglione, S.M. Magrini, PH-0038: RT and concomitant CDDP vs cetuximab for head and neck cancer: long term outcomes of a randomized PH. Poster Highlights: Poster highlights 1 CL: Head & Neck PH-0038: RT and concomitant CDDP vs cetuximab for head and neck cancer: long term outcomes of a randomized PH. [Extracted from the article]

Published
2020
Full Text
View/download PDF

184. SC214 - The outstanding evolution of radical prostatectomy in the last seven years in italy: Comparative analysis on more than 1,500 patients from MIRROR-SIU/LUNA vs. Pros-IT-CNR surveys.

Author

Gacci, M., Artibani, W., Bassi, P., Bertoni, F., Bracarda, S., Carmignani, G., Conti, G., Corvò, R., Graziotti, P., Maggi, S., Magrini, S., Mirone, V., Montironi, R., Morgia, G., Muto, G., Noale, M., Pecoraro, S., Porreca, A., Ricardi, U., and Russi, E.

Subjects
*PROSTATECTOMY, *COMPARATIVE studies, *BIOLOGICAL evolution, *SURVEYING (Engineering), *PATIENTS
Published
2019
Full Text
View/download PDF

190. Topical natural-origin polynucleotides in radiation-induced skin and mucosal toxicity.

Author

Giudici S, Maggio F, Bertocchi M, Lucido MR, Corvò R, and Orsatti M

Subjects
Humans, Atrophy, Skin, Polynucleotides
Abstract

Seventy to 90 percent of patients who have received radiation treatment struggle with radiation skin and mucosal toxicity. The inflicted damage to progenitor cells and local microcirculation makes it more likely that wounds, infections, and fibrosis may occur; lesions of variable severity often co-exist. Acute erythema, hyperpigmentation, and mild desquamation usually wane in weeks and require only minor treatment. Conversely, the management of persistent radiation dermatitis and telangiectasia remains unsatisfactory; chronic lesions may progress to tissue atrophy and disfiguring fibrosis., (This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Published
2022
Full Text
View/download PDF

191. Stereotactic radiotherapy (SRT) for differentiated thyroid cancer (DTC) oligometastases: an AIRO (Italian association of radiotherapy and clinical oncology) systematic review.

Author

Lancellotta V, Fanetti G, Monari F, Mangoni M, Mazzarotto R, Tagliaferri L, Gobitti C, Lodi Rizzini E, Talomo S, Turturici I, Paiar F, Corvò R, Jereczek-Fossa BA, Donato V, and Vianello F

Subjects
Disease-Free Survival, Humans, Medical Oncology, Middle Aged, Retrospective Studies, Adenocarcinoma, Radiosurgery, Thyroid Neoplasms radiotherapy, Thyroid Neoplasms surgery
Abstract

Purpose: The aim of this systematic review was to examine efficacy of stereotactic radiotherapy (SRT) in patients with oligometastatic thyroid cancer., Materials and Methods: A systematic search was conducted by means of PubMed, Scopus, and Cochrane library., Clinicaltrials: gov was searched for ongoing or recently completed trials, and PROSPERO was searched for ongoing or recently completed systematic reviews. We analyzed only clinical studies as full text carried out on patients with oligometastatic thyroid cancer treated with SRT. Conference papers, surveys, letters, editorials, book chapters, and reviews were excluded. Time of publication was restricted to the years 1990-2021., Results: The number of evaluated patients was 146 (267 lesions), and the median age was 58 years. The median 1-year local control (LC) was 82% (range 67.0%-97.1%); the median disease-free survival (DFS) was 12 months (range 4-53); the median 1-year overall survival was 72% (range 66.6%-85.0%); the 3-year cancer-specific survival was 75.0%; and the 4-year cancer-specific survival was 37.5%. No grade 3-5 acute toxicity was reported. No late effects were recorded., Conclusions: SRT for oligometastases from thyroid cancer as salvage therapy is well tolerated and yields high rates of LC and prolonged DFS., (© 2022. Italian Society of Medical Radiology.)

Published
2022
Full Text
View/download PDF

192. The waiting time for prostate cancer treatment in Italy: analysis from the PROS-IT CNR Study.

Author

Gacci M, Greco I, Artibani W, Bassi P, Bertoni F, Bracarda S, Briganti A, Carmignani G, Carmignani L, Conti GN, Corvò R, DE Nunzio C, Fusco F, Graziotti P, Maggi S, Magrini SM, Mirone V, Montironi R, Muto G, Noale M, Pecoraro S, Porreca A, Ricardi U, Russi E, Salonia A, Simonato A, Serni S, Tubaro A, Zagonel V, and Crepaldi G

Subjects
Humans, Male, Prostate pathology, Quality of Life, Waiting Lists, Percutaneous Coronary Intervention, Prostatic Neoplasms diagnosis, Prostatic Neoplasms surgery
Abstract

Background: Prostate cancer (PCa) is the second most common neoplasm in male patients. To date, there's no certain indication about the maximum waiting time (WT) acceptable for treatment beginning and the impact on oncological and functional outcomes has not been well established., Methods: Data from the National Research Council PCa monitoring multicenter project in Italy (Pros-IT CNR) were prospectively collected and analyzed. WT was defined as the time from the bioptical diagnosis of PCa to the first treatment received. Patients were divided in two groups, using a time frame of 90 days. Quality of life was measured through the Italian version of the University of California Los Angeles-Prostate Cancer Index (UCLA-PCI) and of the Short-Form Health Survey (SF-12). The occurrence of upgrading, upstaging, presence of lymph node metastasis and positive surgical margins at the final histopathological diagnosis, and PSA at 12 months follow-up were evaluated., Results: The overall median WT was 93 days. The logistic multivariable model confirmed that age, being resident in Southern regions of Italy and T staging at diagnosis were significantly associated with a WT>90 days. At 6 months from diagnosis the mean SF-12 score for the emotional-psychological component was significantly lower in WT≥90 days group (P=0.0428). Among patients treated with surgical approach, no significant differences in oncological outcomes were found in the two groups., Conclusions: In our study age, clinical T stage and provenance from Southern regions of Italy are associated with a WT>90 days. WT might have no impact on functional and oncological outcome.

Published
2022
Full Text
View/download PDF

193. Health-related quality of life 24 months after prostate cancer diagnosis: an update from the Pros-IT CNR prospective observational study.

Author

Palumbo C, Bruni A, Antonelli A, Artibani W, Bassi P, Bertoni F, Borghetti P, Bracarda S, Cicchetti A, Corvò R, Gacci M, Ingrosso G, Magrini SM, Maruzzo M, Mirone V, Montironi R, Muto G, Noale M, Porreca A, Russi E, Triggiani L, Tubaro A, Valdagni R, Maggi S, and Conti GN

Subjects
Androgen Antagonists therapeutic use, Humans, Male, Prostatectomy, Quality of Life, Percutaneous Coronary Intervention, Prostatic Neoplasms diagnosis, Prostatic Neoplasms therapy
Abstract

Background: This study analyzes patient health-related quality of life (QoL) 24-month after prostate cancer (PCa) diagnosis within the PROState cancer monitoring in ITaly from the National Research Council (Pros-IT CNR) study., Methods: Pros-IT CNR is an ongoing, longitudinal and observational study, considering a convenience sample of patients enrolled at PCa diagnosis and followed at 6, 12, 24, 36, 48 and 60 months from the diagnosis. Patients were grouped according to the treatment received: nerve sparing radical prostatectomy (NSRP), non-nerve sparing radical prostatectomy (NNSRP), radiotherapy (RT), RT plus androgen deprivation (RT plus ADT) and active surveillance (AS). QoL was measured through the Italian versions of SF-12 and UCLA-PCI questionnaires at diagnosis and at 6-12 and 24-month. The minimal clinically important difference (MCID) was defined as half a standard deviation of the baseline domain., Results: Overall, 1537 patients were included in the study. The decline in urinary function exceeded the MCID at each timepoint only in the NSRP and NNSRP groups (at 24 months -14.7, P<0.001 and -19.7, P<0.001, respectively). The decline in bowel function exceeded the MCID only in the RT (-9.1, P=0.02) and RT plus ADT groups at 12 months (-10.3, P=0.001); after 24 months, most patients seem to recover their bowel complaints. The decline in sexual function exceeded the MCID at each timepoint in the NNSRP, NSRP and RT plus ADT groups (at 6 months -28.7, P<0.001, -37.8, P<0.001, -20.4, P<0.001, respectively)., Conclusions: Although all the treatments were relatively well-tolerated over the 24 month period following PCa diagnosis, each had a different impact on QoL.

Published
2022
Full Text
View/download PDF

194. Palliative radiotherapy indications during the COVID-19 pandemic and in future complex logistic settings: the NORMALITY model.

Author

Cellini F, Di Franco R, Manfrida S, Borzillo V, Maranzano E, Pergolizzi S, Morganti AG, Fusco V, Deodato F, Santarelli M, Arcidiacono F, Rossi R, Reina S, Merlotti A, Jereczek-Fossa BA, Tozzi A, Siepe G, Cacciola A, Russi E, Gambacorta MA, Scorsetti M, Ricardi U, Corvò R, Donato V, Muto P, and Valentini V

Subjects
Consensus, Humans, Italy, Pandemics, Practice Guidelines as Topic, Societies, Medical, COVID-19 prevention & control, Neoplasms radiotherapy, Palliative Care methods, Radiation Oncology methods
Abstract

Introduction: The COVID-19 pandemic has challenged healthcare systems worldwide over the last few months, and it continues to do so. Although some restrictions are being removed, it is not certain when the pandemic is going to be definitively over. Pandemics can be seen as a highly complex logistic scenario. From this perspective, some of the indications provided for palliative radiotherapy (PRT) during the COVID-19 pandemic could be maintained in the future in settings that limit the possibility of patients achieving symptom relief by radiotherapy. This paper has two aims: (1) to provide a summary of the indications for PRT during the COVID-19 pandemic; since some indications can differ slightly, and to avoid any possible contradictions, an expert panel composed of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) and the Palliative Care and Supportive Therapies Working Group (AIRO-palliative) voted by consensus on the summary; (2) to introduce a clinical care model for PRT [endorsed by AIRO and by a spontaneous Italian collaborative network for PRT named "La Rete del Sollievo" ("The Net of Relief")]. The proposed model, denoted "No cOmpRoMise on quality of life by pALliative radiotherapy" (NORMALITY), is based on an AIRO-palliative consensus-based list of clinical indications for PRT and on practical suggestions regarding the management of patients potentially suitable for PRT but dealing with highly complex logistics scenarios (similar to the ongoing logistics limits due to COVID-19)., Material and Methods: First, a summary of the available literature guidelines for PRT published during the COVID-19 pandemic was prepared. A systematic literature search based on the PRISMA approach was performed to retrieve the available literature reporting guideline indications fully or partially focused on PRT. Tables reporting each addressed clinical presentation and respective literature indications were prepared and distributed into two main groups: palliative emergencies and palliative non-emergencies. These summaries were voted in by consensus by selected members of the AIRO and AIRO-palliative panels. Second, based on the summary for palliative indications during the COVID-19 pandemic, a clinical care model to facilitate recruitment and delivery of PRT to patients in complex logistic scenarios was proposed. The summary tables were critically integrated and shuffled according to clinical presentations and then voted on in a second consensus round. Along with the adapted guideline indications, some methods of performing the first triage of patients and facilitating a teleconsultation preliminary to the first in-person visit were developed., Results: After the revision of 161 documents, 13 papers were selected for analysis. From the papers, 19 clinical presentation items were collected; in total, 61 question items were extracted and voted on (i.e., for each presentation, more than one indication was provided from the literature). Two tables summarizing the PRT indications during the COVID-19 pandemic available from the literature (PRT COVID-19 summary tables) were developed: palliative emergencies and palliative non-emergencies. The consensus of the vote by the AIRO panel for the PRT COVID-19 summary was reached. The PRT COVID-19 summary tables for palliative emergencies and palliative non-emergencies were adapted for clinical presentations possibly associated with patients in complex clinical scenarios other than the COVID-19 pandemic. The two new indication tables (i.e., "Normality model of PRT indications") for both palliative emergencies and palliative non-emergencies were voted on in a second consensus round. The consensus rate was reached and strong. Written forms facilitating two levels of teleconsultation (triage and remote visits) were also developed, both in English and in Italian, to evaluate the patients for possible indications for PRT before scheduling clinical visits., Conclusion: We provide a comprehensive summary of the literature guideline indications for PRT during COVID-19 pandemic. We also propose a clinical care model including clinical indications and written forms facilitating two levels of teleconsultation (triage and remote visits) to evaluate the patients for indications of PRT before scheduling clinical visits. The normality model could facilitate the provision of PRT to patients in future complex logistic scenarios., (© 2021. The Author(s).)

Published
2021
Full Text
View/download PDF

195. Adjuvant radiotherapy and radioiodine treatment for locally advanced differentiated thyroid cancer: systematic review and meta-analysis.

Author

Dicuonzo S, Pedretti S, Mangoni M, Monari F, Fanetti G, Borsatti E, Lombardi D, Vianello F, Iacobone M, Corvò R, Magrini SM, Pappagallo G, Arcangeli S, and D'Angelillo RM

Subjects
Disease Management, Humans, Iodine Radioisotopes administration & dosage, Neoplasm Grading, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Thyroid Neoplasms etiology, Thyroid Neoplasms mortality, Treatment Outcome, Iodine Radioisotopes therapeutic use, Radiotherapy, Adjuvant adverse effects, Radiotherapy, Adjuvant methods, Thyroid Neoplasms pathology, Thyroid Neoplasms radiotherapy
Abstract

Background: Treatment for locally advanced differentiated thyroid cancer is surgery followed by radioiodine while the role of adjuvant external beam radiotherapy (EBRT) is debated., Methods: The panel of the Italian Association of Radiotherapy and Clinical Oncology developed a clinical recommendation on the addition of EBRT to radioiodine after surgery for locally advanced differentiated thyroid cancer by using the Grades of Recommendation, Assessment, Development, and Evaluation methodology and the Evidence to Decision framework. A systematic review with meta-analysis about this topic was conducted with a focus on outcome of benefits and toxicity., Results: Locoregional control was improved by EBRT while no considerable toxicity impact was reported., Conclusion: The panel judged uncertain the benefit/harms balance; final recommendation was conditional both for EBRT + radioiodine and radioiodine alone in the adjuvant setting.

Published
2021
Full Text
View/download PDF

196. Ten Daily Fractions for Whole Breast Cancer Irradiation: Long Term Results.

Author

Belgioia L, Fozza A, Trapani L, Carmisciano L, Cavagnetto F, Agostinelli S, Guenzi M, Friedman D, Fregatti P, and Corvò R

Subjects
Dose Fractionation, Radiation, Female, Follow-Up Studies, Humans, Neoplasm Recurrence, Local radiotherapy, Radiotherapy, Adjuvant, Breast Neoplasms radiotherapy, Breast Neoplasms surgery, Mastectomy, Segmental
Abstract

Background/aim: To report the feasibility and oncological outcomes in breast cancer patients treated with a short hypofractionated radiotherapy schedule., Patients and Methods: We evaluated 380 breast cancer patients treated with ten daily fractions of radiotherapy up to 39 Gy on tumor bed. Primary endpoint was local relapse rate (LRR). Secondary endpoints were overall survival (OS) and metastasis-free survival (MFS)., Results: The median follow up was 5.0 years. Two- and 5-year LRR rates were 0.2 and 2%, respectively. Two- and 5-year MFS rates were 96.1% and 90.5%, respectively. Two and 5-year OS rates were 97.4% and 95%, respectively., Conclusion: This short schedule may represent an alternative option to standard mild hypofractionated radiotherapy in breast cancer patients due to its excellent feasibility and very low recurrence rate., (Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)

Published
2021
Full Text
View/download PDF

197. The Italian Association of Radiotherapy and Oncology Recommendation for Breast Tumor Recurrence: Grades of Recommendation, Assessment, Development and Evaluation Criteria.

Author

Bottero M, Borzillo V, Pergolizzi S, Jereczek-Fossa BA, Ippolito E, Frezza GP, Fortunato L, Corvò R, Pappagallo GL, Arcangeli S, Magrini SM, and D'Angelillo RM

Abstract

Salvage mastectomy is currently considered the standard of care for ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery (BCS) and postoperative radiotherapy (RT). Alternative treatment options for these patients, such as a second BCS followed by repeated RT, have been suggested. The panel of the Italian Association of Radiotherapy and Clinical Oncology developed clinical recommendations for second BCS followed by re-irradiation over mastectomy alone for women with IBTR using the Grades of Recommendation, Assessment, Development, and Evaluation methodology and the evidence to decision framework. The following outcomes were identified by the panel: locoregional control, metastasis-free survival, overall survival, and cancer-specific survival; acute and late toxicity, specific late toxicity, second locoregional tumor, and death related to treatment. An Embase and PubMed literature search was performed by two independent authors. Five retrospective observational studies were eligible for inclusion in the present analysis. According to the reports in the literature and our analysis, the advantages of second quadrantectomy and re-irradiation (re-QUART) outweigh its side effects, with overall good rates of survival and adequate toxicity without increasing costs. Given the very low level of evidence, the panel stated that a second BCS plus re-irradiation can be considered as an alternative to salvage mastectomy for selected patients with IBTR., Competing Interests: The authors declare that they have no competing interests., (© 2021 Korean Breast Cancer Society.)

Published
2021
Full Text
View/download PDF

198. Survival and toxicity of weekly cisplatin chemoradiotherapy versus three-weekly cisplatin chemoradiotherapy for head and neck cancer: A systematic review and meta-analysis endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO).

Author

De Felice F, Belgioia L, Alterio D, Bonomo P, Maddalo M, Paiar F, Denaro N, Corvò R, Merlotti A, Bossi P, Pappagallo GL, D' Angelillo RM, Magrini SM, and Arcangeli S

Subjects
Chemoradiotherapy adverse effects, Cisplatin adverse effects, Humans, Italy, Medical Oncology, Antineoplastic Agents adverse effects, Head and Neck Neoplasms drug therapy
Abstract

Purpose: To evaluate efficacy and toxicity of weekly cisplatin chemoradiotherapy versus three-weekly cisplatin chemoradiotherapy and identify differences in clinical outcomes and severe toxicity rate., Methods: PICOS/PRISMA methods were used to identify studies on PubMed, EMBASE and Cochrane Library, 2005-2019., Results: Six randomized clinical trials (554 patients) were identified. Weekly cisplatin was not associated with significant overall survival (HR 1.13, 95 % CI 0.84-1.51) and progression-free survival (HR 1.23, 95 %CI 0.91-1.65) improvement compared with three-weekly regimen. Severe acute toxicity (RR 0.95), treatment compliance to chemotherapy (RR 1.67) and radiotherapy (RR 0.61) were similar between regimens., Conclusion: Weekly cisplatin is not associated with better clinical outcomes compared to three-weekly cisplatin. Three-weekly cisplatin chemoradiotherapy should be considered the standard approach in the management of locally advanced head and neck cancer. Methodologically robust RCTs designs are needed to improve the quality of evidence. Differences on long-term toxicity and cost-effectiveness remain to be tested., (Copyright © 2021 Elsevier B.V. All rights reserved.)

Published
2021
Full Text
View/download PDF

199. Development of Exhaustion and Acquisition of Regulatory Function by Infiltrating CD8+CD28- T Lymphocytes Dictate Clinical Outcome in Head and Neck Cancer.

Author

Fenoglio D, Belgioia L, Parodi A, Missale F, Bacigalupo A, Tarke A, Incandela F, Negrini S, Vecchio S, Altosole T, Vlah S, Astone G, Costabile F, Ascoli A, Ferrera F, Schenone G, De Palma R, Signori A, Peretti G, Corvò R, and Filaci G

Abstract

Head and neck squamous cell carcinoma (HNSCC) has a poor clinical outcome despite the presence of a rich CD8+ T cell tumor infiltrate in the majority of patients. This may be due to alterations of tumor infiltrating CD8+ T cells. Here, we performed a characterization of HNSCC infiltrating CD8+ T cells in a cohort of 30 patients. The results showed that differential intratumoral frequency of CD8+CD28+ T cells, CD8+CD28- T cells, and CD8+CD28-CD127-CD39+ Treg distinguished between HNSCC patients who did or did not respond to treatment. Moreover, high PD1 expression identified a CD8+CD28- T cell subpopulation, phenotypically/functionally corresponding to CD8+CD28-CD127-CD39+ Treg, which showed a high expression of markers of exhaustion. This observation suggests that development of exhaustion and acquisition of regulatory properties may configure the late differentiation stage for intratumoral effector T cells, a phenomenon we define as effector-to-regulatory T cell transition.

Published
2021
Full Text
View/download PDF

200. How radical prostatectomy procedures have changed over the last 10 years in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study.

Author

Gacci M, Artibani W, Bassi P, Bertoni F, Bracarda S, Briganti A, Carmignani G, Carmignani L, Conti G, Corvò R, De Nunzio C, Fusco F, Graziotti P, Greco I, Maggi S, Magrini SM, Mirone V, Montironi R, Morgia G, Muto G, Noale M, Pecoraro S, Porreca A, Ricardi U, Russi E, Russo G, Salonia A, Simonato A, Serni S, Tomasini D, Tubaro A, Zagonel V, and Crepaldi G

Subjects
Aged, Humans, Italy, Logistic Models, Male, Middle Aged, Prospective Studies, Time Factors, Prostatectomy methods, Prostatectomy trends, Prostatic Neoplasms surgery
Abstract

Purpose: Therapeutic strategies for prostate cancer (PCa) have been evolving dramatically worldwide. The current article reports on the evolution of surgical management strategies for PCa in Italy., Methods: The data from two independent Italian multicenter projects, the MIRROR-SIU/LUNA (started in 2007, holding data of 890 patients) and the Pros-IT-CNR project (started in 2014, with data of 692 patients), were compared. Differences in patients' characteristics were evaluated. Multivariable logistic regression models were used to identify characteristics associated with robot-assisted (RA) procedure, nerve sparing (NS) approach, and lymph node dissection (LND)., Results: The two cohorts did not differ in terms of age and prostate-specific antigen (PSA) levels at biopsy. Patients enrolled in the Pros-IT-CNR project more frequently were submitted to RA (58.8% vs 27.6%, p < 0.001) and NS prostatectomy (58.4% vs. 52.9%, p = 0.04), but received LND less frequently (47.7% vs. 76.7%, p < 0.001), as compared to the MIRROR-SIU/LUNA patients. At multivariate logistic models, Lower Gleason Scores (GS) and PSA levels were significantly associated with RA prostatectomy in both cohorts. As for the MIRROR-SIU/LUNA data, clinical T-stage was a predictor for NS (OR = 0.07 for T3, T4) and LND (OR = 2.41 for T2) procedures. As for Pros-IT CNR data, GS ≥ (4 + 3) and positive cancer cores ≥ 50% were decisive factors both for NS (OR 0.29 and 0.30) and LND (OR 7.53 and 2.31) strategies., Conclusions: PCa management has changed over the last decade in Italian centers: RA and NS procedures without LND have become the methods of choice to treat newly medium-high risk diagnosed PCa.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results